| 摘要: |
| 目的：分析重组人干扰素α1b（IFNα1b）儿科雾化使用现状，为进一步规范其使用提供参考。方法：从我院医院信息系统（HIS）和电子病历系统提取儿内科2018年9月使用IFNα1b患儿的一般情况、临床诊断、用法用量、疗程、合并疾病等资料，进行回顾性统计分析。结果：共收集926例使用IFNα1b的儿内科住院患儿，分布在6个病区；平均年龄2.87岁；主要诊断有社区获得性肺炎（44.82%）、支气管肺炎（28.29%）、急性支气管炎（18.47%）等；疗程（5.84±1.58）d；重症病例治疗剂量（1.91±0.60）μg/kg，非重症病例（1.5±0.53）μg/kg。治疗总有效率92.55%，未观察到明显不良反应。结论：儿科使用IFNα1b雾化治疗有较好的临床效果，耐受性和安全性较高，但在剂量、疗程、禁忌证等方面存在一些不合理使用情况，临床应给予重点关注，提高合理用药水平。 |
| 关键词: 儿科 干扰素α1b 雾化吸入 使用分析 |
| DOI：doi:10.13407/j.cnki.jpp.1672.108X.2019.12.014 |
|
| 基金项目:成都药学会赞邦药学科研基金,编号201703。 |
|
| Analysis of the Utilization of Inhalation of Recombinant Human Interferon α1b in Pediatric Departments |
| Guo Wenmei, Li Gen, Tao Wanjun, Jiang Yongxian, Li Li |
| (Chengdu Women’s and Children’s Hospital, Sichuan Chengdu 610091, China) |
| Abstract: |
| Objective: To analyze the current utilization of inhalation of recombinant human interferon α1b (IFNα1b) in the six pediatric departments of our hospital, to provide reference for further regulating its use in these departments. Methods: The information concerned about the general situation, clinical diagnosis, drug dose, course of treatment and comorbidity of the inpatients who received IFNα1b between Sep. 1st and Sep. 30th were extracted from the hospital information system (HIS) and Electronic Medical Record system (EMR) of our hospital, followed by retrospectively statistic analyzing. Results: The 926 inpatients who used IFNα1b were distributed in the pediatric pulmonology department, the pediatric neurology department, the pediatric nephrology department, pediatric gastroenterology department, the pediatric cardiology department and the pediatric hematology department, including 472 male and 454 female, the ratio of male to female was 1:0.96, the mean patient age was 2.87 years; the principle diagnosis were community-acquired pneumonia(415 cases, 44.82%), bronchopneumonia (262 cases, 28.29%), acute bronchitis (171 cases, 18.47%), acute upper respiratory tract infection(58 cases, 6.26%) and bronchiolitis (15 cases, 1.62%); the treatment duration was (5.84±1.58) days; the dose was (1.91±0.60) μg/kg in severe cases and (1.5±0.53) μg/kg in non-severe cases. Conclusion: According to the analysis, there were some irrational use in the aspects of contraindication, drug dose and duration in the utilization of inhalation of IFNα1b, thus more attention should be paid in these aspects in the clinical application, and the clinical use of IFNα1b should be improved. |
| Key words: pediatric department recombinant human interferon α1b inhalation utilization analysis |
